Myran Daniel T, Pugliese Michael, Tanuseputro Peter, Cantor Nathan, Rhodes Emily, Taljaard Monica
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Addiction. 2022 Jul;117(7):1952-1960. doi: 10.1111/add.15834. Epub 2022 Feb 17.
Recreational cannabis was legalized in Canada in October 2018. Initially, the Government of Ontario (Canada's largest province) placed strict limits on the number of cannabis retail stores before later removing these limits. This study measured changes in cannabis-attributable emergency department (ED) visits over time, corresponding to different regulatory periods.
Interrupted time-series design using population-level data. Two policy periods were considered; recreational cannabis legalization with strict store restrictions (RCL, 17 months) and legalization with no store restrictions [recreational cannabis commercialization (RCC), 15 months] which coincided with the COVID-19 pandemic. Segmented Poisson regression models were used to examine immediate and gradual effects in each policy period.
Ontario, Canada.
All individuals aged 15-105 years (n = 13.8 million) between January 2016 and May 2021.
Monthly counts of cannabis-attributable ED visits per capita and per all-cause ED visits in individuals aged 15+ (adults) and 15-24 (young adults) years.
We observed a significant trend of increasing cannabis-attributable ED visits pre-legalization. RCL was associated with a significant immediate increase of 12% [incident rate ratio (IRR) = 1.12, 95% confidence interval (CI) = 1.02-1.23] in rates of cannabis-attributable ED visits followed by significant attenuation of the pre-legalization slope (monthly slope change IRR = 0.98, 95% CI = 0.97-0.99). RCC and COVID-19 were associated with immediate significant increases of 22% (IRR = 1.22, 95% CI = 1.09-1.37) and 17% (IRR = 1.17, 95% CI = 1.00-1.37) in rates of cannabis-attributable visits and the proportion of all-cause ED visits attributable to cannabis, respectively, with insignificant increases in monthly slopes. Similar patterns were observed in young adults.
In Ontario, Canada, cannabis-attributable emergency department visits stopped increasing over time following recreational cannabis legalization with strict retail controls but then increased during a period coinciding with cannabis commercialization and the COVID-19 pandemic.
2018年10月,娱乐用大麻在加拿大实现合法化。最初,安大略省政府(加拿大最大的省份)对大麻零售店的数量设定了严格限制,随后取消了这些限制。本研究测量了在不同监管时期,因大麻导致的急诊科就诊人数随时间的变化。
使用人群水平数据的中断时间序列设计。考虑了两个政策时期;有严格店铺限制的娱乐用大麻合法化时期(RCL,17个月)和无店铺限制的合法化时期[娱乐用大麻商业化时期(RCC),15个月],这一时期恰逢新冠疫情。采用分段泊松回归模型来检验每个政策时期的即时和渐进影响。
加拿大安大略省。
2016年1月至2021年5月期间所有年龄在15 - 105岁的个体(n = 1380万)。
15岁及以上(成年人)和15 - 24岁(年轻人)个体中,人均因大麻导致的急诊科就诊次数以及所有病因导致的急诊科就诊次数中因大麻导致的就诊次数占比的月度计数。
我们观察到在合法化之前,因大麻导致的急诊科就诊次数有显著增加的趋势。RCL与因大麻导致的急诊科就诊率立即显著增加12%[发病率比(IRR)= 1.12,95%置信区间(CI)= 1.02 - 1.23]相关,随后合法化前的斜率显著衰减(月度斜率变化IRR = 0.98,95% CI = 0.97 - 0.99)。RCC和新冠疫情分别与因大麻导致的就诊率立即显著增加22%(IRR = 1.22,95% CI = 1.09 - 1.37)以及所有病因导致的急诊科就诊次数中因大麻导致的就诊比例立即显著增加17%(IRR = 1.17,95% CI = 1.00 - 1.37)相关,月度斜率增加不显著。在年轻人中也观察到了类似的模式。
在加拿大安大略省实行严格零售管控的娱乐用大麻合法化后,因大麻导致的急诊科就诊次数随时间停止增加,但在与大麻商业化和新冠疫情同时发生的时期又有所增加。